Entospletinib

Drug Profile

Entospletinib

Alternative Names: ENTO; GS-9973

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator CGI Pharmaceuticals
  • Developer CGI Pharmaceuticals; Gilead Sciences; Lymphoma Academic Research Organisation
  • Class Amines; Anti-inflammatories; Antineoplastics; Antirheumatics; Imidazoles; Indazoles; Morpholines; Pyrazines; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Haematological malignancies; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase I Acute lymphoblastic leukaemia; Cancer
  • No development reported Inflammation; Rheumatoid arthritis

Most Recent Events

  • 18 May 2017 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, First-line therapy) in Japan (PO) (NCT03135028)
  • 18 May 2017 Phase-I clinical trials in Haematological malignancies (Monotherapy, Treatment-resistant) in Japan (PO) (NCT03135028)
  • 16 May 2017 Phase-I/II clinical trials in Diffuse large B cell lymphoma (Newly diagnosed) in Belgium (PO) (EudraCT2016-003103-56)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top